Table 4

Correlation between PD-L1 expression in tumours/PD-1 expression in TILs and TIL score with pCR by subtype 

TNBCp*HR−/HER2+p*HR+/HER2−p*
N (%)% pCR rateN (%)% pCR rateN (%)% pCR rate
PD-L1 expression
positive
negative
40 (49)
41 (51)
22.5 (9/40)
36.6 (15/41)
0.1613 (32)
28 (68)
38.5 (5/13)
14.3 (4/28)
0.089 (20)
35 (80)
0 (0/9)
2 (2/35)
0.46
PD-1 expression
 positive
negative
26 (32)
56 (68)
30.8 (8/26)
30.3 (17/56)
0.978 (20)
32 (80)
25.0 (2/8)
21.9 (7/32)
0.85 6 (14)
36 (86)
 0 (0/6)
8.3 (3/36)
0.46
TIL score
High
Low
67 (73)
25 (27)
37.3 (25/67)
16.0 (4/25)
0.0523 (55)
19 (45)
30.4 (7/23)
10.5 (2/19)
0.12 8 (17)
38 (82)
12.5 (1/8)
 5.3 (2/38)
0.45
  • *p Values were calculated between each of the three factors and pCR by using the χ2 exact test.

  • HER2, human epidermal growth factor receptor 2; HR, hormone receptors; pCR, pathological complete response; PD-1, programmed cell death-1; PD-L1,  programmed cell death-ligand 1; TIL, tumour-infiltrating lymphocytes; TNBC, triple-negative breast cancer.